Automate Your Wheel Strategy on BMEA
With Tiblio's Option Bot, you can configure your own wheel strategy including BMEA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMEA
- Rev/Share 0.0333
- Book/Share 0.7846
- PB 2.4599
- Debt/Equity 0.2758
- CurrentRatio 2.2549
- ROIC -3.62
- MktCap 110052846.0
- FreeCF/Share -3.1086
- PFCF -0.9666
- PE -0.7114
- Debt/Assets 0.144
- DivYield 0
- ROE -1.5273
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | BMEA | Piper Sandler | -- | Overweight | -- | $7 | June 3, 2025 |
| Upgrade | BMEA | Rodman & Renshaw | Neutral | Buy | -- | $18 | Sept. 27, 2024 |
| Upgrade | BMEA | Truist | Hold | Buy | -- | $54 | Sept. 27, 2024 |
| Initiation | BMEA | CapitalOne | -- | Overweight | -- | $25 | Aug. 29, 2024 |
News
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for icovamenib, the company's investigational oral menin inhibitor, at the 85th Scientific Sessions of the American Diabetes Association (ADA) June 20–23, 2025 in Chicago.
Read More
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Biomea Fusion (BMEA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will feature two oral presentations, one poster presentation, and chair a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025).
Read More
About Biomea Fusion, Inc. (BMEA)
- IPO Date 2021-04-16
- Website https://biomeafusion.com
- Industry Biotechnology
- CEO Michael J. M. Hitchcock
- Employees 79